{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:57:45Z","timestamp":1794013065191,"version":"4.8.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010854","name":"Jiangsu Provincial Commission of Health and Family Planning","doi-asserted-by":"publisher","award":["LGY2016018"],"award-info":[{"award-number":["LGY2016018"]}],"id":[{"id":"10.13039\/501100010854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.cyto.2025.156968","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T05:11:30Z","timestamp":1748409090000},"page":"156968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The relationship between interleukin and ankylosing spondylitis"],"prefix":"10.1016","volume":"192","author":[{"given":"Zekai","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoji","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2025.156968_bb0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2025.156968_bb0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss clinical quality management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2025.156968_bb0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40265-019-01075-3","article-title":"Secukinumab: a review in ankylosing spondylitis","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.cyto.2025.156968_bb0020","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","article-title":"Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis","volume":"14","author":"Gravallese","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.cyto.2025.156968_bb0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/cei.12670","article-title":"The interleukin (IL)-23\/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment","volume":"183","author":"Jethwa","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0030","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","article-title":"The IL-23-IL-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.cyto.2025.156968_bb0035","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0040","doi-asserted-by":"crossref","first-page":"28278","DOI":"10.18632\/oncotarget.16004","article-title":"Association of IL-1A and IL-1B polymorphisms with ankylosing spondylitis among the Chinese Han population: a case-control study","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cyto.2025.156968_bb0045","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.2147\/IJN.S216199","article-title":"Advances in nanomedicine for the treatment of ankylosing spondylitis","volume":"14","author":"Xi","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.cyto.2025.156968_bb0050","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.cca.2018.08.022","article-title":"NLRP3 inflammasomes and NLRP3 inflammasome-derived proinflammatory cytokines in peripheral blood mononuclear cells of patients with ankylosing spondylitis","volume":"486","author":"Kim","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cyto.2025.156968_bb0055","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.4049\/jimmunol.1300274","article-title":"Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase\/prostaglandin E2 pathway, independent of IL-23","volume":"191","author":"Paulissen","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111697","article-title":"Evaluation of interleukins (IL-1\u03b1, IL-1Ra, IL-12, IL-17A, IL-31, and IL-33) and chemokines (CXCL10 and CXCL16) in the serum of male patients with ankylosing spondylitis","volume":"129","author":"Muhsin","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cyto.2025.156968_bb0065","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11845-020-02366-5","article-title":"Interleukin-1\u03b2, interleukin-6, and interleukin-17A as indicators reflecting clinical response to celecoxib in ankylosing spondylitis patients","volume":"190","author":"Zhang","year":"2021","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.cyto.2025.156968_bb0070","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1006\/geno.1994.1076","article-title":"A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes","volume":"19","author":"Nicklin","year":"1994","journal-title":"Genomics"},{"key":"10.1016\/j.cyto.2025.156968_bb0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5152\/eurjrheum.2018.18150","article-title":"IL-1A gene variation in relation to cytokine levels and clinical characteristics in ankylosing spondylitis","volume":"6","author":"Nossent","year":"2019","journal-title":"Eur. J. Rheumatol."},{"key":"10.1016\/j.cyto.2025.156968_bb0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/ni.1818","article-title":"Regulatory T cells exert checks and balances on self tolerance and autoimmunity","volume":"11","author":"Wing","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0085","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2025.156968_bb0090","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0095","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1995-7645(12)60205-3","article-title":"Expression of IL-2 and IL-11 and its significance in patients with ankylosing spondylitis","volume":"6","author":"Liu","year":"2013","journal-title":"Asian Pac J Trop Med"},{"key":"10.1016\/j.cyto.2025.156968_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103172","article-title":"The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial","volume":"144","author":"Lorenzon","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cyto.2025.156968_bb0105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13075-020-02226-8","article-title":"TNF-\u03b1 inhibitor therapy can improve the immune imbalance of CD4+ T cells and negative regulatory cells but not CD8+ T cells in ankylosing spondylitis","volume":"22","author":"Yang","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cyto.2025.156968_bb0110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cyto.2015.01.038","article-title":"History of interleukin-4","volume":"75","author":"Paul","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2025.156968_bb0115","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.4049\/jimmunol.150.12.5436","article-title":"Structural comparison and chromosomal localization of the human and mouse IL-13 genes","volume":"150","author":"McKenzie","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08830189809084486","article-title":"Interleukin-4 and interleukin-13: their similarities and discrepancies","volume":"17","author":"Chomarat","year":"1998","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cells10113000","article-title":"Significance of interleukin (IL)-4 and IL-13 in inflammatory arthritis","volume":"10","author":"Iwaszko","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.cyto.2025.156968_bb0130","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1159\/000374026","article-title":"IL-4 modulates macrophage polarization in ankylosing spondylitis","volume":"35","author":"Lin","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.cyto.2025.156968_bb0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.cyto.2025.156968_bb0140","first-page":"1","article-title":"IL-6 signal transduction and its physiological roles: the signal orchestration model","volume":"149","author":"Kamimura","year":"2003","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"10.1016\/j.cyto.2025.156968_bb0145","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","article-title":"Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/labmed\/lmab029","article-title":"Serum IL-6 and TNF-\u03b1 levels are correlated with disease severity in patients with ankylosing spondylitis","volume":"53","author":"Du","year":"2022","journal-title":"Lab. Med."},{"key":"10.1016\/j.cyto.2025.156968_bb0155","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/ard.2007.071605","article-title":"Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab","volume":"67","author":"Visvanathan","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2025.156968_bb0160","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/art.38404","article-title":"Histomorphologic and histomorphometric characteristics of zygapophyseal joint remodeling in ankylosing spondylitis","volume":"66","author":"Bleil","year":"2014","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2025.156968_bb0165","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.biopha.2016.09.091","article-title":"Annexin A2, up-regulated by IL-6, promotes the ossification of ligament fibroblasts from ankylosing spondylitis patients","volume":"84","author":"Li","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cyto.2025.156968_bb0170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.cyto.2025.156968_bb0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbrc.2022.06.081","article-title":"IL-6 activates pathologic Th17 cell via STAT 3 phosphorylation in inflammatory joint of ankylosing spondylitis","volume":"620","author":"Lee","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cyto.2025.156968_bb0180","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/intimm\/dxm045","article-title":"IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state","volume":"19","author":"Nishihara","year":"2007","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0185","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/intimm\/dxv038","article-title":"The expanding family of regulatory B cells","volume":"27","author":"Mauri","year":"2015","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0190","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev-immunol-020711-074934","article-title":"Immune regulatory function of B cells","volume":"30","author":"Mauri","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0195","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/978-1-0716-1237-8_10","article-title":"Characterization and activity of TIM-1 and IL-10-reporter expressing regulatory B cells","volume":"2270","author":"Mohib","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.cyto.2025.156968_bb0200","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2016.01171","article-title":"The immune dysfunction in ankylosing spondylitis patients","volume":"11","author":"Duan","year":"2017","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.cyto.2025.156968_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.653611","article-title":"Influence of IL10 (rs1800896) polymorphism and TNF-\u03b1, IL-10, IL-17A, and IL-17F serum levels in ankylosing spondylitis","volume":"12","author":"Braga","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0210","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.4049\/jimmunol.1103180","article-title":"IL-10 triggers changes in macrophage phenotype that promote muscle growth and regeneration","volume":"189","author":"Deng","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0215","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.immuni.2019.03.020","article-title":"IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation","volume":"50","author":"Ouyang","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2025.156968_bb0220","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41586-024-07098-5","article-title":"IL-10 constrains sphingolipid metabolism to limit inflammation","volume":"627","author":"York","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cyto.2025.156968_bb0225","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2567.2010.03402.x","article-title":"Interleukin-10-induced gene expression and suppressive function are selectively modulated by the PI3K-Akt-GSK3 pathway","volume":"132","author":"Antoniv","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.cyto.2025.156968_bb0230","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1089\/dna.2015.3046","article-title":"Defective function of CD24(+)CD38(+) regulatory B cells in ankylosing spondylitis","volume":"35","author":"Chen","year":"2016","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.cyto.2025.156968_bb0235","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cytogfr.2021.04.002","article-title":"The cytokine interleukin-11 crucially links bone formation, remodeling and resorption","volume":"60","author":"Kespohl","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cyto.2025.156968_bb0240","doi-asserted-by":"crossref","DOI":"10.1128\/mSystems.01173-20","article-title":"The salivary microbiota, cytokines, and metabolome in patients with ankylosing spondylitis are altered and more Proinflammatory than those in healthy controls","volume":"6","author":"Lv","year":"2021","journal-title":"mSystems"},{"key":"10.1016\/j.cyto.2025.156968_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 Axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints","volume":"19","author":"Boutet","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2025.156968_bb0250","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s42255-023-00846-3","article-title":"Interleukin-17 as a key player in neuroimmunometabolism","volume":"5","author":"Douglas","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.cyto.2025.156968_bb0255","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/ard-2022-223146","article-title":"Card9\/neutrophil signalling axis promotes IL-17A-mediated ankylosing spondylitis","volume":"83","author":"Rosenzweig","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2025.156968_bb0260","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cyto.2025.156968_bb0265","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cyto.2025.156968_bb0270","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/ng.2007.17","article-title":"Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants","volume":"39","author":"Burton","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cyto.2025.156968_bb0275","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/rheumatology\/kes254","article-title":"Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritis","volume":"52","author":"Jadon","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2025.156968_bb0280","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1038\/srep10314","article-title":"Integrated genomics identifies convergence of ankylosing spondylitis with global immune mediated disease pathways","volume":"5","author":"Uddin","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2025.156968_bb0285","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13075-018-1582-3","article-title":"IL-17A induces osteoblast differentiation by activating JAK2\/STAT3 in ankylosing spondylitis","volume":"20","author":"Jo","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cyto.2025.156968_bb0290","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nri2691","article-title":"The IL-1 family: regulators of immunity","volume":"10","author":"Sims","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0295","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.951535","article-title":"Pathogenic roles and diagnostic utility of interleukin-18 in autoinflammatory diseases","volume":"13","author":"Shimizu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.919973","article-title":"Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: biological role in induction, regulation, and treatment","volume":"13","author":"Ihim","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0305","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1186\/s13018-023-04200-x","article-title":"Molecular mechanisms of AMPK\/YAP\/NLRP3 signaling pathway affecting the occurrence and development of ankylosing spondylitis","volume":"18","author":"Fu","year":"2023","journal-title":"J. Orthop. Surg. Res."},{"key":"10.1016\/j.cyto.2025.156968_bb0310","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1756-185X.2009.01448.x","article-title":"Fetuin-a and interleukin-18 levels in ankylosing spondylitis","volume":"13","author":"Sari","year":"2010","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.cyto.2025.156968_bb0315","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-immunol-032414-112134","article-title":"The immunobiology of interleukin-27","volume":"33","author":"Yoshida","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0320","article-title":"An updated advancement of bifunctional IL-27 in inflammatory autoimmune diseases","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0325","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10238-014-0281-x","article-title":"Elevated serum level of IL-27 and VEGF in patients with ankylosing spondylitis and associate with disease activity","volume":"15","author":"Lin","year":"2015","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.cyto.2025.156968_bb0330","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.4049\/jimmunol.0900568","article-title":"IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells","volume":"183","author":"Murugaiyan","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0335","doi-asserted-by":"crossref","first-page":"11495","DOI":"10.1073\/pnas.1002099107","article-title":"Identification of an IL-27\/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation","volume":"107","author":"Murugaiyan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cyto.2025.156968_bb0340","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.12619","article-title":"Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family","volume":"281","author":"Cayrol","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cyto.2025.156968_bb0345","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2025.156968_bb0350","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2025.156968_bb0355","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.0606854104","article-title":"IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo","volume":"104","author":"Carriere","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cyto.2025.156968_bb0360","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s10067-011-1843-x","article-title":"Serum levels of IL-33 is increased in patients with ankylosing spondylitis","volume":"30","author":"Han","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.cyto.2025.156968_bb0365","doi-asserted-by":"crossref","first-page":"13463","DOI":"10.1073\/pnas.0906988106","article-title":"IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells","volume":"106","author":"Guo","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cyto.2025.156968_bb0370","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.631603","article-title":"IL-33 gene polymorphisms as potential biomarkers of disease susceptibility and response to TNF inhibitors in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis patients","volume":"12","author":"Iwaszko","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0375","article-title":"IL-33-induced TREM2(+) macrophages promote pathological new bone formation through CREG1-IGF2R Axis in ankylosing spondylitis","volume":"e2500952","author":"Hao","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.cyto.2025.156968_bb0380","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41467-017-00838-4","article-title":"IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease","volume":"8","author":"Dambuza","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cyto.2025.156968_bb0385","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.molimm.2019.01.009","article-title":"Ebi3 promotes T- and B-cell division and differentiation via STAT3","volume":"107","author":"Ma","year":"2019","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0390","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ni.2227","article-title":"The composition and signaling of the IL-35 receptor are unconventional","volume":"13","author":"Collison","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0395","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/imm.13044","article-title":"Interleukin-35 in immune-related diseases: protection or destruction","volume":"157","author":"Zhang","year":"2019","journal-title":"Immunology"},{"key":"10.1016\/j.cyto.2025.156968_bb0400","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nm.3554","article-title":"Interleukin-35 induces regulatory B cells that suppress autoimmune disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2025.156968_bb0405","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s10067-022-06137-8","article-title":"Interleukin-35 promotes Breg expansion and interleukin-10 production in CD19(+) B cells in patients with ankylosing spondylitis","volume":"41","author":"Zhang","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.cyto.2025.156968_bb0410","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40259-023-00635-0","article-title":"Molecular engineering of Interleukin-2 for enhanced therapeutic activity in autoimmune diseases","volume":"38","author":"Tomasovic","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.cyto.2025.156968_bb0415","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL-2: Biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.cyto.2025.156968_bb0420","doi-asserted-by":"crossref","DOI":"10.4110\/in.2022.22.e9","article-title":"Targeted immunotherapy for autoimmune disease","volume":"22","author":"Jung","year":"2022","journal-title":"Immune Netw."},{"key":"10.1016\/j.cyto.2025.156968_bb0425","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3899\/jrheum.110955","article-title":"Interleukin 6 blockade in spondyloarthritis","volume":"39","author":"Koumakis","year":"2012","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cyto.2025.156968_bb0430","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2025.156968_bb0435","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2025.156968_bb0440","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000592","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2","volume":"3","author":"Marzo-Ortega","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.cyto.2025.156968_bb0445","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2025.156968_bb0450","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/annrheumdis-2020-217309","article-title":"Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression","volume":"79","author":"Watad","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2025.156968_bb0455","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of Ustekinumab in axial Spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2025.156968_bb0460","doi-asserted-by":"crossref","first-page":"E1349","DOI":"10.1097\/BRS.0000000000003169","article-title":"Treg-promoted new bone formation through suppressing TH17 by secreting Interleukin-10 in ankylosing spondylitis","volume":"44","author":"Xu","year":"2019","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.1016\/j.cyto.2025.156968_bb0465","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1038\/s41467-021-26750-6","article-title":"Targeting chondrocytes for arresting bony fusion in ankylosing spondylitis","volume":"12","author":"Shao","year":"2021","journal-title":"Nat. Commun."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:40:48Z","timestamp":1762353648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466625001152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":93,"alternative-id":["S1043466625001152"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2025.156968","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The relationship between interleukin and ankylosing spondylitis","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2025.156968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156968"}}